Results 111 to 120 of about 240,836 (199)

The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis

Circulation
espite favorable efficacy and safety profiles of factor Xa (FXa) inhibitor anticoagulants, associated mortality can occur in ≈ 9% of patients within 30 days of major extracranial bleeding, including gastro-intestinal (GI) bleeding.
Deborah M. Siegal, N. Forbes, J. Eikelboom, Jan Beyer-Westendorf, Alexander T. Cohen, Li-Zhen Xu, S. Connolly, Mark Crowther   +7 more
semanticscholar   +1 more source

Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate

Clinical and applied thrombosis/hemostasis
Introduction Andexanet alfa (AA) - zhzo, recombinant coagulation factor Xa, is an approved antidote for oral Xa inhibitors (apixaban and rivaroxaban). Unfractionated heparin (UFH) is commonly used for therapeutic, interventional, and surgical indications.
Fakiha Siddiqui, D. Hoppensteadt, W. Jeske, E. Ramacciotti, Alfonso Tafur, J. Fareed   +5 more
semanticscholar   +1 more source

Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage

Hospital Pharmacy
Objective: Andexanet alfa is approved for the reversal of life-threatening or uncontrolled bleeding due to factor-Xa inhibitors. Data are limited on outcomes for patients who receive both andexanet alfa and 4-factor prothrombin complex concentrate (4F ...
Sophia Pathan
semanticscholar   +1 more source

Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data

CNS Drugs
Andexanet alfa is a specific reversal agent for factor Xa inhibitors with immediate reversal of their anticoagulant effect. Andexanet alfa is currently approved for use in patients treated with rivaroxaban and apixaban who have life-threatening or ...
S. Frol, J. Oblak, M. Šabovič, Pawel Kermer   +3 more
semanticscholar   +1 more source

Reversal of direct oral anticoagulants

Vascular Health and Risk Management, 2017
Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a ...
Almegren M
doaj  

Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testing

Thrombosis Journal
Bleeding events in patients receiving direct oral anticoagulation (DOAC) can be life-threatening even at therapeutic DOAC plasma concentrations, as anticoagulation impairs hemostasis and should therefore be identified immediately after hospital admission.
Lars Heubner, Oliver Grottke, Oliver Vicent, Peter Markus Spieth, Jan Beyer-Westendorf   +4 more
doaj   +1 more source

Andexanet alfa—The first 150 days [PDF]

American Journal of Hematology, 2018
Sarah E. Culbreth, Jessica Rimsans, Katelyn Sylvester, Daniel J. Pallin, Jean M. Connors   +4 more
openaire   +2 more sources

Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects

, 2020
Introduction Investigation of factors (F) VIII and IX is common, with testing important for diagnosis or exclusion of haemophilia A or B, associated acquired conditions and factor inhibitors.
Gilmore, G., Dean, E., Bonar, R., Favaloro, E.J., Arunachalam, S., Mohammed, S., Baker, R.   +6 more
core  

Acute coronary syndrome during active infusion of andexanet alfa. [PDF]

JAAPA
Dalal V, Hu GJ, Panico RA, Rodricks MB.
europepmc   +1 more source

Temporal Coagulation Biomarker Profiles After Andexanet Alfa Use for Procedure-Related Cardiac Tamponade. [PDF]

J Cardiovasc Electrophysiol
Shimojo M, Inden Y, Kitahara T, Hiramatsu S, Tanaka Y, Hiramatsu T, Fukushima T, Adachi K, Teraoka T, Ota R, Yanagisawa S, Tsuji Y.   +11 more
europepmc   +1 more source